The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators
Abstract
Background and Purpose— Stroke risk increases with age in patients who have nonvalvular atrial fibrillation. It is uncertain whether the efficacy of stroke prevention therapies in atrial fibrillation changes as patients age. The objective of this study was to determine the effect of age on the relative efficacy of oral anticoagulants (OAC) and antiplatelet (AP) therapy (including acetylsalicylic acid and triflusal) on ischemic stroke, serious bleeding, and vascular events in patients with atrial fibrillation. Methods— This is an analysis of the Atrial Fibrillation Investigators database, which contains patient level-data from randomized trials of stroke prevention in atrial fibrillation. We used Cox regression models with age as a continuous variable that controlled for sex, year of randomization, and history of cerebrovascular disease, diabetes, hypertension, and congestive heart failure. Outcomes included ischemic stroke, serious bleeding (intracranial hemorrhage or systemic bleeding requiring hospitalization, transfusion, or surgery), and cardiovascular events (ischemic stroke, myocardial infarction, systemic embolism, or vascular death). Results— The analysis included 8932 patients and 17 685 years of observation from 12 trials. Patient age increased risk of ischemic stroke (adjusted hazard ratio per decade increase 1.45; 95% CI, 1.26 to 1.66), serious bleeding (1.61; 1.47 to 1.77), and cardiovascular events (1.43; 1.33 to 1.53). Compared with placebo, OAC and AP significantly reduced the risk of ischemic stroke (OAC, 0.36; 0.29 to 0.45; AP, 0.81; 0.72 to 0.90) and cardiovascular outcomes (OAC, 0.59; 0.52 to 0.66; AP, 0.81; 0.75 to 0.88), whereas OAC increased risk of serious bleeding (1.56; 1.03 to 2.37). The relative benefit of OAC versus placebo or AP did not vary by patient age for any outcome. Compared with placebo, the relative benefit of AP for preventing ischemic stroke decreased significantly as patients aged ( P =0.01). Conclusions— As patients with atrial fibrillation age, the relative efficacy of AP to prevent ischemic stroke appears to decrease, whereas it does not change for OAC. Because stroke risk increases with age, the absolute benefit of OAC increases as patients get older.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Petersen, P., Godtfredsen, J., Boysen, G., Andersen, E., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,820
Self-citationRegression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling
Royston, P., & Altman, D. G. (1994) · Applied Statistics · doi:10.2307/2986270 · Cited by 1,798
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Stroke Prevention in Atrial Fibrillation Study. Final results.
(1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
(1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,530
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
Ezekowitz, M. D., Bridgers, S. L., James, K. E., Carliner, N. H., Colling, C. L., Gornick, C. C., Krause-Steinrauf, H., Kurtzke, J. F., Nazarian, S. M., Radford, M. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272002 · Cited by 1,160
Self-citationCanadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,111
Self-citationWarfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,067
Rothwell, P., Coull, A., Silver, L., Fairhead, J., Giles, M., Lovelock, C., Redgrave, J., Bull, L., Welch, S., Cuthbertson, F., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67702-1 · Cited by 967
van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B. (2002) · JAMA · doi:10.1001/jama.288.19.2441 · Cited by 714
Self-citationSTROKEPREVENTIONINATRIALFIBRIL (1994) · The Lancet · doi:10.1016/s0140-6736(94)91577-6 · Cited by 621
Effect of Study Setting on Anticoagulation Control
van Walraven, C., Jennings, A., Oake, N., Fergusson, D., & Forster, A. J. (2006) · Chest · doi:10.1378/chest.129.5.1155 · Cited by 487
Self-citationSauerbrei, W., & Royston, P. (1999) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/1467-985x.00122 · Cited by 475
Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis
Takkouche, B., Cadarso-Suarez, C., & Spiegelman, D. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009981 · Cited by 380
Sauerbrei, W., Meier-Hirmer, C., Benner, A., & Royston, P. (2006) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2005.07.015 · Cited by 351
Gulløv, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., Godtfredsen, J., & Boysen, G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.14.1513 · Cited by 301
Self-citationSato, H., Ishikawa, K., Kitabatake, A., Ogawa, S., Maruyama, Y., Yokota, Y., Fukuyama, T., Doi, Y., Mochizuki, S., Izumi, T., et al. (2006) · Stroke · doi:10.1161/01.str.0000198839.61112.ee · Cited by 282
Ragland, D. R. (1992) · Epidemiology · doi:10.1097/00001648-199209000-00009 · Cited by 280
Hart, R. G., Pearce, L. A., Miller, V. T., Anderson, D. C., Rothrock, J. F., Albers, G. W., & Nasco, E. (2000) · Cerebrovascular Diseases · doi:10.1159/000016023 · Cited by 265
Self-citationHylek, E. M., D’Antonio, J., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2006) · Stroke · doi:10.1161/01.str.0000209239.71702.ce · Cited by 250
Austin, P. C., & Brunner, L. J. (2004) · Statistics in Medicine · doi:10.1002/sim.1687 · Cited by 240
Self-citationPérez-Gómez, F., Alegría, E., Berjón, J., Iriarte, J. A., Zumalde, J., Salvador, A., & Mataix, L. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.05.084 · Cited by 232
Hellemons, B. S. P., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H. J. A., Lemmens, T., van Ree, J. W., & Knottnerus, J. A. (1999) · BMJ · doi:10.1136/bmj.319.7215.958 · Cited by 226
Self-citationContrast sonography for detection of vesicoureteral reflux
Kaneko, K., Kuwatsuru, R., Fukuda, Y., Yamataka, A., Yabuta, K., Katayama, H., & Miyano, T. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92123-7 · Cited by 222
1 (1995) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/s1052-3057(10)80166-1 · Cited by 138
Zhao, L. P., & Kolonel, L. N. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116520 · Cited by 108
Bias and Efficiency Loss Due to Categorizing an Explanatory Variable
Taylor, J. M. G., & Yu, M. (2002) · Journal of Multivariate Analysis · doi:10.1006/jmva.2001.2045 · Cited by 89
Becher, H., Grau, A., Steindorf, K., Buggle, F., & Hacke, W. (2000) · PubMed · Cited by 37
Statistical Power and Sample Size Calculations
Selvin, S. (2004) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195172805.003.03 · Cited by 15
Cited by
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Metadata
- Authors
- van Walraven, C., Hart, R. G., Connolly, S., Austin, P. C., Mant, J., Hobbs, F. D. R., Koudstaal, P. J., Petersen, P., Perez-Gomez, F., Knottnerus, J. A., Boode, B., Ezekowitz, M. D., & Singer, D. E.
- Venue
- Stroke
- Published
- 2009-04
- Volume
- 40
- Issue
- 4
- Pages
- 1410-1416
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2081669586
- Cited by
- 312
- References
- 37
- FWCI
- 20.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.